OBP Ondine Biomed

 
TIDMOBP 
 
Ondine Biomedical Inc.: AIM Notification 
                                    Ondine Biomedical Inc.: AIM Notification 
 
VANCOUVER,  BRITISH COLUMBIA--(Marketwire - Dec. 21, 2010) - Ondine Biomedical Inc. ("Ondine" or  the  "Company") 
(TSX:OBP)(AIM)OBP) today announces that a Director of the Company and his spouse have transferred shares to their 
adult  children as outlined below, together with the Director's subsequent ownership interest in the Company  and 
the combined subsequent ownership interest of the Director, his spouse, and a company controlled by them: 
 
Name                                                                                                 Merrill Biel 
 
Relationship to the Company                                                                              Director 
 
Date the transaction was reported to the Company                                                December 20, 2010 
 
Date of transaction (all documentation completed)                                               December 20, 2010 
 
Effective Date of the transfer                                                                  December 16, 2010 
 
Nature of the transaction                                                              Transfer to Adult Children 
 
Type of security disposed                                                                           Common shares 
 
Number of securities disposed: 
 By the Director                                                                                           33,520 
 By the Director's spouse                                                                                  33,520 
 
Price per security                                                                                     Cdn. $0.72 
 
Nature and extent of each of the above's interest in the                           100% direct ownership interest 
 transaction 
 
Number of shares held in the Company by the Director immediately 
 subsequent to completion of the transaction                                                              376,039 
 
Percentage direct ownership in the Company of the Director 
 immediately subsequent to completion of the transaction                                                    4.40% 
 
Number of shares held in the Company by the Director, the 
 Director's spouse, and a company controlled by the Director and 
 his spouse immediately subsequent to completion of the 
 transaction.                                                                                             613,539 
 
Percentage ownership in the Company by the Director, the 
 Director's spouse, and a company controlled by the Director and 
 his spouse immediately subsequent to completion of the 
 transaction (7.54% assuming all options held by the director are 
 exercised)                                                                                                 7.18% 
 
Close period                                                                                                   No 
 
Other                                                               The  shares  transferred are subject  to:  (i) 
                                                                     a contractual  hold period expiring June  7, 
                                                                     2011, and  (iii)  a  Reg S restriction  in 
                                                                     the  United States 
 
For further information: 
 
Carolyn Cross, Chairman and CEO                          Canaccord Genuity Limited, Nominated Adviser 
Ondine Biomedical Inc.                                   Ryan Gaffney 
(604) 669-0555                                           +4420 7050 6500 
ccross@ondinebio.com 
 
 
Ondine Biomedical Inc. 
 

Ondine Biomed (LSE:OBP)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Ondine Biomed (LSE:OBP)
Historical Stock Chart
Von Mai 2023 bis Mai 2024